Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse af Vemurafenib og Obinutuzumab sammenlignet med Cladribine og Rituximab hos mennesker med hårcelleleukæmi (HCL)

16. november 2026 opdateret af: Memorial Sloan Kettering Cancer Center

Et randomiseret, multicenter, fase II-studie af Vemurafenib Plus Obinutuzumab vs. Cladribine Plus Rituximab hos patienter med tidligere ubehandlet hårcelleleukæmi (HCL)

The researchers are doing this study to compare the safety of vemurafenib in combination with obinutuzumab to the standard of approach of cladribine in combination with rituximab. The researchers will look at which treatment causes fewer or milder side effects. Researchers think vemurafenib and obinutuzumab (non-chemotherapy drugs) may cause fewer side effects compared with the usual approach of chemotherapy drugs. They will also compare the two approaches to see which approach is more effective at eliminating cancer cells.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

86

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

  • Navn: Mark Geyer, MD
  • Telefonnummer: 646-608-3745

Studiesteder

    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02115
        • Ikke rekrutterer endnu
        • Dana Farber Cancer Institute
        • Kontakt:
          • Eric Winer, MD
          • Telefonnummer: (617) 632-6876
    • Minnesota
      • Rochester, Minnesota, Forenede Stater, 55905
        • Ikke rekrutterer endnu
        • Mayo Clinic Cancer Center
        • Kontakt:
          • Sameer Parikh, M.B.B.S.
          • Telefonnummer: 507-218-0772
    • New Jersey
      • Basking Ridge, New Jersey, Forenede Stater, 07920
        • Rekruttering
        • Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)
        • Kontakt:
          • Jae Park, MD
          • Telefonnummer: 646-608-3743
      • Middletown, New Jersey, Forenede Stater, 07748
        • Rekruttering
        • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
        • Kontakt:
          • Jae Park, MD
          • Telefonnummer: 646-608-3743
      • Montvale, New Jersey, Forenede Stater, 07645
        • Rekruttering
        • Memorial Sloan Kettering Bergen (Limited Protocol Activities)
        • Kontakt:
          • Jae Park, MD
          • Telefonnummer: 646-608-3743
    • New York
      • Commack, New York, Forenede Stater, 11725
        • Rekruttering
        • Memorial Sloan Kettering Cancer Commack - Suffolk (Limited Protocol Activities)
        • Kontakt:
          • Jae Park, MD
          • Telefonnummer: 646-608-3743
      • Harrison, New York, Forenede Stater, 10604
        • Rekruttering
        • Memorial Sloan Kettering Westchester (All Protocol Activities)
        • Kontakt:
          • Jae Park, MD
          • Telefonnummer: 646-608-3743
      • New York, New York, Forenede Stater, 10065
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
        • Kontakt:
          • Jae Park, MD
          • Telefonnummer: 646-608-3743
      • Uniondale, New York, Forenede Stater, 11553
        • Rekruttering
        • Memorial Sloan Kettering Nassau (Limited Protocol Activities)
        • Kontakt:
          • Jae Park, MD
          • Telefonnummer: 646-608-3743
    • Ohio
      • Columbus, Ohio, Forenede Stater, 43210
        • Rekruttering
        • Ohio State University
        • Kontakt:
          • Seema Bhat, MD
          • Telefonnummer: 614-293-3196

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Patients must be ≥ 18 years of age

  • Histologically confirmed classical HCL by the enrolling institution

  • Presence of BRAF V600E mutation as confirmed by PCR, NGS or immunohistochemistry. If patient is known to have negative BRAF mutation, repeat testing is advisable as well as discussion with the main study principal investigator.

  • Has not received any prior therapy for the disease

  • Patients who meet the standard treatment initiation criteria, as defined by ANC ≤1.0, Hgb ≤ 10.0 or PLT ≤100K

  • ECOG performance status of 0 - 2

  • Acceptable pre-study organ function during screening as defined as:

    • Total bilirubin ≤ 1.5 times the upper limit of normal (ULN), except in patients with known Gilbert's syndrome who may be enrolled if direct bilirubin ≤ 3 x ULN);
    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5x ULN; and
    • Serum creatinine ≤ 1.5x ULN
  • Electrocardiogram (ECG) without evidence of clinically significant ventricular arrhythmias or ischemia as determined by the investigator and a rate-corrected QT interval (QTc, Bazett's formula) of < 480 msec

  • For women of childbearing potential, agreement to the use of two acceptable methods of contraception, including one barrier method, during the study and for 6 months after discontinuation of vemurafenib and cladribine, and 18 months after discontinuation of rituximab and obinutuzumab

  • For men with female partners of childbearing potential, agreement to use a latex condom and to advise their female partner to use an additional method of contraception during the study and for 6 months after discontinuation of vemurafenib

  • Negative serum pregnancy test within 7 days of commencement of treatment in women of childbearing potential

Exclusion Criteria:

  • Have had previous treatment for HCL, including purine analogs, vemurafenib, rituximab, obinutuzumab, and other investigational agents. Previous treatment with transfusions and other supportive care such as G-CSF and erythropoietin are allowed.

  • Known hypersensitivity to any of the study drugs.

  • Patients with known long QT syndrome or uncorrectable electrolyte abnormalities

  • Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis.

  • Presence of positive test results for hepatitis B virus (HBV), hepatitis B surface antigen (HBsAg) or hepatitis C (HCV) antibody

    ° Patients with occult or prior HBV infection (defined as positive total hepatitis B core antibody [HBcAb] and negative HBsAg) may be included if HBV DNA is undetectable. These patients must be willing to undergo monthly DNA testing and take HBV viral prophylaxis such as entecavir.

  • Known infection with HIV or human T-cell leukemia virus 1 (HTLV-1)

  • Active uncontrolled infection, e.g. persistent bacteremia, supplemental oxygen or pressor supports, etc.

  • Live vaccination within 28 days of randomization

  • Patients with concurrent active malignancies as defined by malignancies requiring any therapy other than expectant observation or hormonal therapy, with the exception of squamous and basal cell carcinoma of the skin, in situ cervical cancer, adequately treated stage I/II cancer from which the patient is current in complete remission, or any other cancer from which the patient has been disease free for five years

  • Malabsorption syndrome or other condition that precludes enteral route of administration

  • Patients with HCL variant (as defined by absence of expression of CD25)

  • Pregnant or lactating, or intending to become pregnant during the study

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Vemurafenib plus Obinutuzumab

Patients assigned to the study arm will receive vemurafenib orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles. Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks. Obinutuzumab infusions will be administered on days 1, 8 and 15 during the cycle 2 and every 4 weeks during the cycle 3 and 4 of treatment.

Vemurafenib orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles.

Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks.

Aktiv komparator: Standard treatment of Cladribine plus Rituximab

Patients assigned to the SOC arm will receive cladribine IV on days 1-5 concurrently with rituximab IV per week for 8 times, i.e., weekly x8 from day 1.

Cladribine IV on days 1-5 concurrently with rituximab.

Rituximab on days 1-5 concurrently with rituximab.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
incidences of ≥ grade 3 treatment-related toxicities
Tidsramme: within 6 months of treatment

per CTCAE v5.0 within first 6 months from the start of the treatment to account delayed toxicities of the treatments

within 6 months of treatment

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
complete remission
Tidsramme: 2 years

Response will be determined by the Consensus Resolution response criteria.

Complete response (CR)

  • A morphological absence of hairy cells in the blood and bone marrow
  • A normalization of any organomegaly and cytopenias
2 years
partial response
Tidsramme: 2 years

Partial response (PR)

°A normalization of cytopenias

°≥50% reduction in organomegaly and bone marrow hairy cells.

2 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Jae Park, MD, Memorial Sloan Kettering Cancer Center

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

9. september 2024

Primær færdiggørelse (Anslået)

9. september 2027

Studieafslutning (Anslået)

9. september 2027

Datoer for studieregistrering

Først indsendt

13. august 2024

Først indsendt, der opfyldte QC-kriterier

15. august 2024

Først opslået (Faktiske)

20. august 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

17. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

16. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner